Healthcare / BiotechnologyNasdaqCM
$1.24
-0.04 (-3.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-104.6M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$102M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-352.5%
↓Gross Margin
N/A
•Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-26.6%
FCF CAGR
—
FCF margin
-136074.5%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65343.0 · net income $-84.9M · FCF $-88.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $65343.00 | $65343.00 | $217756.00 | $832010.00 | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M | $40.6M | $10.5M | $13.5M | $4.1M | $9.8M | $6.1M | $9.1M |
| Net Income | $-84.9M | $-84.9M | $-107.3M | $-135.1M | $-279.8M | $-303.7M | $-166.4M | $-119.4M | $-97.0M | $-88.2M | $-73.7M | $-29.2M | $-36.1M | $-66.0M | $-19.7M | $-15.3M | $-17.6M | $-24.4M |
| EBITDA | $-82.0M | $-82.0M | $-103.9M | $-130.4M | $-270.9M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -1.81 | -1.81 | -3.95 | -6.09 | -14.04 | -17.45 | -12.84 | -14.52 | -12.60 | -13.08 | -12.12 | -5.28 | -7.68 | -17.16 | -6.96 | — | — | — |
| Operating Margin | -132871.3% | -132871.3% | -51616.9% | -16036.7% | -2607.4% | -16972.3% | -1674.2% | -2702.1% | -308.7% | -198.1% | -215.5% | -84.5% | -377.7% | -145.1% | -570.4% | -220.9% | -312.8% | -153.0% |
| Net Margin | -130000.0% | -130000.0% | -49254.3% | -16239.9% | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% | -71.9% | -345.4% | -490.3% | -477.6% | -155.7% | -286.6% | -267.7% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.39 | 0.39 | 0.17 | 0.26 | 0.14 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.04 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-88.9M | $-88.9M | $-104.6M | $-124.7M | $-217.2M | $-216.9M | $-179.5M | $-98.8M | $-75.6M | $-73.5M | $-65.3M | $-15.2M | $-31.2M | $-15.6M | $-22.5M | $-19.9M | $-12.1M | $-14.1M |
| Returns | ||||||||||||||||||
| ROE | -352.5% | -352.5% | -156.6% | -115.1% | -125.8% | -76.0% | -36.1% | -3474.7% | -111.5% | -61.9% | -59.8% | -16.6% | -32.5% | -125.9% | -57.3% | -32.2% | -37.9% | — |
| Valuation | ||||||||||||||||||
| P/B | 2.41 | 2.41 | 0.78 | 1.63 | 1.68 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -70.0% | -70.0% | -73.8% | -91.9% | — | -76.1% | 80.2% | -86.5% | -27.8% | 19.4% | -12.8% | 288.0% | -22.4% | 227.0% | -58.0% | 59.4% | -32.6% | — |
| EPS Growth | 54.2% | 54.2% | 35.1% | 56.6% | — | -35.9% | 11.6% | -15.2% | 3.7% | -7.9% | -129.5% | 31.3% | 55.2% | -146.6% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.95 → -1.81
Residual
-41.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.